9 results on '"Balm, A.J.M."'
Search Results
2. Variation in head and neck cancer care in the Netherlands A retrospective cohort evaluation of incidence, treatment and outcome
- Author
-
Ridder, M. de, Balm, A.J.M., Jong, R.J.B. de, Terhaard, C.H.J., Takes, R.P., Slingerland, M., Dik, E., Sedee, R.J.E., Visscher, J.G.A.M. de, Bouman, H., Willems, S.M., Wouters, M.W., Smeele, L.E., Dijk, B.A.C. van, and Dutch Head Neck Res Grp
- Subjects
Treatment ,Survival ,Epidemiology ,Journal Article ,Quality of care ,Head and neck cancer ,Outcome - Abstract
BACKGROUND: To explore variation in numbers and treatment between hospitals that treat head and neck cancer (HNC) in the Netherlands. MATERIAL AND METHODS: Patient, tumor and treatment characteristics were collected from the Netherlands Cancer Registry, while histopathological features were obtained by linkage to the national pathology record register PALGA. Inter-hospital variation in volume, stage, treatment, pathologically confirmed loco-regional recurrence and overall survival rate was evaluated by tumor site. RESULTS: In total, 2094 newly diagnosed patients were included, ranging from 65 to 417 patients in participating hospitals treating HNC in 2008. Oral cavity cancer was mainly treated by surgery only, ranging from 46 to 82% per hospital, while the proportion of surgery with (chemo)radiotherapy ranged from 18 to 40%. Increasing age, male sex, and high stage were associated with a higher hazard of dying. In oropharynx cancer, the use of (chemo)radiotherapy varied from 31 to 82% between hospitals. We found an indication that higher volume was associated with a lower overall hazard of dying for the total group, but not by subsite. Low numbers, e.g. for salivary gland, nasopharynx, nasal cavity and paranasal sinus, did not permit all desired analyses. CONCLUSION: This study revealed significant interhospital variation in numbers and treatment of especially oropharyngeal and oral cavity cancer. This study is limited because we had to rely on data recorded in the past for a different purpose. To understand whether this variation is unwanted, future research should be based on prospectively collected data, including detailed information on recurrences, additional case-mix information and cause of death.
- Published
- 2017
3. Late follow-up of the randomized radiation and concomitant high-dose intra-arterial or intravenous cisplatin (RADPLAT) trial for advanced head and neck cancer
- Author
-
Heukelom, J., Lopez-Yurda, M., Balm, A.J.M., Wijers, O.B., Buter, J., Gregor, T., Wiggenraad, R., Boer, J.P. de, Tan, I.B., Verheij, M., Sonke, J.J., and Rasch, C.R.
- Subjects
late results ,toxicity ,radiation oncology ,head and neck cancer ,intra-arterial cisplatin ,chemoradiotherapy - Abstract
Background. The radiation and concomitant high-dose intra-arterial or intravenous cisplatin (RADPLAT) phase III trial compared intra-arterial (IA) to intravenous (IV) cisplatin-based chemoradiation for head and neck cancer. Long-term efficacy and toxicity are reported after a median follow-up of 7.5 years.Methods. Patients with inoperable squamous cell carcinoma (SCC) of the oropharynx, oral cavity, or hypopharynx, were randomized between radiotherapy (RT) + IA cisplatin 150 mg/m(2), followed by systemic rescue or RT + I. V. cisplatin 100 mg/m(2). RT consisted of 46 Gy to the affected and elective areas, followed by a boost of 24 Gy.Results. Among 237 patients, 57 recurred locally, 35 regionally, and 80 locoregionally. There were 32 second primary tumors, 65 distant metastases, and 154 deaths. Locoregional control and overall survival were not different between the treatment arms. Late dysphagia was worse in the I.V. arm (log-rank p=.014).Conclusion. IA cisplatin did not improve tumor control compared to I.V. administered cisplatin, despite the higher dose in IA delivery of the drug. (C) 2015 Wiley Periodicals, Inc.
- Published
- 2016
4. Sensorineural hearing loss in patients with head and neck cancer after chemoradiotherapy and radiotherapy: A systematic review of the literature
- Author
-
Theunissen, E.A.R., Bosma, S.C.J., Zuur, C.L., Spijker, R., Baan, S. van der, Dreschler, W.A., Boer, J.P. de, Balm, A.J.M., Rasch, C.R.N., Faculteit der Geneeskunde, MKA AMC (OII, ACTA), and Maxillofacial Surgery (AMC)
- Subjects
ototoxicity ,SDG 3 - Good Health and Well-being ,otorhinolaryngologic diseases ,head and neck cancer ,sensorineural hearing loss ,radiotherapy ,chemoradiotherapy - Abstract
BackgroundBoth radiotherapy (RT) and cisplatin-based chemoradiotherapy (CRT) in patients with head and neck cancer may cause sensorineural hearing loss (SNHL). The purpose of this review was to provide more insight into SNHL because of CRT compared to RT.MethodsComprehensive search of Medline and Embase with the terms radiotherapy combined with ototoxicity, head and neck squamous cell carcinoma, and synonyms.ResultsOf the 2507 studies found, 21 were included in this study. Pooled analysis could not be committed because of heterogeneity. Incidence rates of SNHL after RT and CRT varied considerably, with percentages ranging from 0% to 43% and 17% to 88%, respectively. Factors that influenced the risk of SNHL were radiation dose to the cochlea, follow-up time, age, baseline hearing level, and cisplatin dose.ConclusionThe wide range of SNHL incidence rates makes it impossible to draw any conclusions on the severity of RT- and CRT-induced ototoxicity. To allow for future comparison of study outcomes, development of uniform criteria is of utmost importance. (c) 2014 Wiley Periodicals, Inc. Head Neck37: 281-292, 2015
- Published
- 2015
- Full Text
- View/download PDF
5. Long-Term Hearing Loss After Chemoradiation in Patients With Head and Neck Cancer
- Author
-
Theunissen, E.A.R., Zuur, C.L., Bosma, S.C.J., Lopez-Yurda, M., Hauptmann, M., Baan, S. van der, Boer, J.P. de, Molen, L. van der, Rasch, C.R.N., Dreschler, W.A., Balm, A.J.M., Maxillofacial Surgery (AMC), Faculteit der Geneeskunde, and MKA AMC (OII, ACTA)
- Subjects
ototoxicity ,SDG 3 - Good Health and Well-being ,Chemoradiation ,otorhinolaryngologic diseases ,cisplatin ,head and neck cancer ,hearing loss - Abstract
Objectives/HypothesisThe purpose of this study was to determine whether concomitant chemoradiation (CCRT)-induced hearing loss is progressive over time or not.Study DesignLong-term (LT) follow-up study.MethodsBetween 1999 and 2004, 158 patients with head and neck cancer were treated with intravenous (IV) CCRT (n = 80) or intraarterial CCRT (n = 78). Audiometry was performed before, short-term (ST), and LT posttreatment. Differences in hearing were assessed with a multivariable linear regression analysis, incorporating the effect of aging.ResultsLong-term audiometry (median 4.5 years) was available in 67 patients (42%). At ST follow-up, a deterioration of 21.6 decibel was seen compared to baseline at pure-tone averages (PTA) 8-10-12.5 kHz. At LT follow-up, this deterioration further increased with 5 decibel (P = 0.005). Only in CCRT-IV patients was a significant progressive treatment-induced hearing loss seen, at PTA 8-10-12.5 kHz (P = 0.005), PTA 1-2-4 kHz air conduction (P = 0.014), and PTA 0.5-1-2 kHz bone conduction (P = 0.045).ConclusionCCRT-induced hearing impairment was progressive over time, especially in higher frequencies and only in CCRT-IV patients, with a modest deterioration of 5 decibel 4.5 years post-treatment.
- Published
- 2014
- Full Text
- View/download PDF
6. Variation in head and neck cancer care in the Netherlands: A retrospective cohort evaluation of incidence, treatment and outcome.
- Author
-
de Ridder, M., Balm, A.J.M., Baatenburg de Jong, R.J., Terhaard, C.H.J., Takes, R.P., Slingerland, M., Dik, E., Sedee, R.J.E., de Visscher, J.G.A.M., Bouman, H., Willems, S.M., Wouters, M.W., Smeele, L.E., and van Dijk, B.A.C.
- Subjects
HEAD & neck cancer treatment ,CANCER radiotherapy ,SURVIVAL analysis (Biometry) ,CANCER-related mortality ,CANCER relapse ,DISEASE incidence - Abstract
Background To explore variation in numbers and treatment between hospitals that treat head and neck cancer (HNC) in the Netherlands. Material and methods Patient, tumor and treatment characteristics were collected from the Netherlands Cancer Registry, while histopathological features were obtained by linkage to the national pathology record register PALGA. Inter-hospital variation in volume, stage, treatment, pathologically confirmed loco-regional recurrence and overall survival rate was evaluated by tumor site. Results In total, 2094 newly diagnosed patients were included, ranging from 65 to 417 patients in participating hospitals treating HNC in 2008. Oral cavity cancer was mainly treated by surgery only, ranging from 46 to 82% per hospital, while the proportion of surgery with (chemo)radiotherapy ranged from 18 to 40%. Increasing age, male sex, and high stage were associated with a higher hazard of dying. In oropharynx cancer, the use of (chemo)radiotherapy varied from 31 to 82% between hospitals. We found an indication that higher volume was associated with a lower overall hazard of dying for the total group, but not by subsite. Low numbers, e.g. for salivary gland, nasopharynx, nasal cavity and paranasal sinus, did not permit all desired analyses. Conclusion This study revealed significant interhospital variation in numbers and treatment of especially oropharyngeal and oral cavity cancer. This study is limited because we had to rely on data recorded in the past for a different purpose. To understand whether this variation is unwanted, future research should be based on prospectively collected data, including detailed information on recurrences, additional case-mix information and cause of death. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
7. Is locally advanced head and neck cancer 'increasing' in the Netherlands? The paradox of absolute numbers, standardized incidence rates and proportional share.
- Author
-
van Beers, M.A., Schreuder, W.H., Balm, A.J.M., and van Dijk, B.A.C.
- Subjects
- *
HEAD & neck cancer , *HYPOPHARYNGEAL cancer , *LARYNGEAL cancer , *ORAL cancer , *CANCER patients , *SQUAMOUS cell carcinoma - Abstract
• Locally advanced head and neck cancer is defined in various ways. • Netherlands Cancer Registry data show an increase of locally advanced oral and oropharynx cancer. • Standardized rates of locally advanced hypopharynx and larynx cancer have declined recent years. • The proportionate share of locally advanced larynx cancer has increased. • There is an urgent need for standardization of the definition locally advanced head and neck cancer. Several reports have indicated that locally advanced head and neck cancer (LAHNC) has increased in the past decade. However, incidence trends cannot be easily compared because slightly different definitions of LAHNC were used. To investigate if the incidence of locally advanced disease (LAD) in the oral cavity, oropharynx, hypopharynx and larynx is indeed increasing over time, considering the growing and ageing population in the Netherlands. Data were obtained from the Netherlands Cancer Registry (NCR). Primary head and neck squamous cell carcinomas of the oral cavity, oropharynx, hypopharynx and larynx diagnosed between 1989 and 2017 were included. Yearly numbers and European standardized incidence rates (ESRs) were reported by extent of disease. The annual percentage change (APC) over time in ESRs was calculated to assess trends. Absolute numbers and ESRs of LAD increased over time for oral cavity and most prominently for oropharynx carcinomas (before 1996, APC: 0.4, 95%CI: 0.1; 0.8 and APC: 5.7 (95%CI: 3.1; 8.4) after 1996: 1.5 (1.0; 2.0) respectively. For hypopharynx cancer the absolute number and ESR of LAD increased until 1997 and declined with 0.8% per year since 1997. Absolute numbers of patients with larynx cancer stayed stable over time, while ESR decreased (APC: −0.8 (95%CI: −1.1; −0.6)). The perception of an increasing trend in LAD in the Netherlands can be attributed to the increasing incidence of oral cavity and oropharynx carcinomas. For LAD of the hypopharynx a decreasing trend was observed. In larynx cancer, the proportional share of LAD of the larynx increased, even though incidence rates declined. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
8. The epidemiology of head and neck squamous cell carcinoma in The Netherlands during the era of HPV-related oropharyngeal squamous cell carcinoma. Is there really evidence for a change?
- Author
-
van Monsjou, H.S., Schaapveld, M., van den Brekel, M.W.M., and Balm, A.J.M.
- Subjects
- *
EPIDEMIOLOGY , *HEAD & neck cancer treatment , *SQUAMOUS cell carcinoma , *PAPILLOMAVIRUSES , *HEAD tumors , *NECK tumors , *VERTEBRATES , *VIRUS diseases , *OROPHARYNGEAL cancer - Abstract
Background: Several recent studies have shown that incidence of oropharyngeal carcinomas is rising in the Western World. This increase has been attributed to changes in the etiology of oropharyngeal carcinomas with a growing role for infections with Human Papilloma viruses. This nationwide study evaluates and compares trends in incidence, clinical behavior and tumor characteristics of oropharyngeal and oral squamous cell cancer.Methods: This study comprised all 16,480 patients with primary squamous cell carcinoma of the oral tongue (OTSCC), oral cavity excluding oral tongue (OCSCC), and oropharynx (OPSCC) diagnosed from 1989 through 2008 in The Netherlands. We assessed trends in age-standardized incidence, second cancer risk and subsite specific relative survival (RS) over time.Results: Incidence of OTSCC and OPSCC in males and incidence of all subsites in females increased significantly from 1989 through 2008. In males increases in incidence were largely restricted to the 50-64 year age group (estimated annual percentage change 2.2% and 3.2% for OTSCC and OPSCC, respectively), while in females incidence increased for most age groups. The incidence of OCSCC (excl. oral tongue) and OPSCC before 50 years of age decreased. Patients with OPSCC showed the poorest prognosis with a relative survival of 41.6% after 5 years and 29.4% after 10 years (P<0.001) over the entire period 1989-2008. However survival increased substantially for OPSCC patients over time (5-year RS of 37.2% in 1989-1993 to 47.6% in 2004-2008, P<0.001).Conclusion: Although incidence of OPSCC did increase since 1989, especially in females, similar increases were seen for OCSCC (excl. oral tongue) and OTSCC. Our study does not appear to support that HPV is the main contributor to a rising incidence of OPSCC as the effects of changes in smoking and alcohol use cannot be discounted. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
9. Prognostic significance of radiologically determined neck node volume in head and neck cancer: A systematic review
- Author
-
Lodder, W.L., Pameijer, F.A., Rasch, C.R.N., van den Brekel, M.W.M., and Balm, A.J.M.
- Subjects
- *
HEAD & neck cancer , *RADIOTHERAPY , *CANCER patients , *LYMPH nodes , *SYSTEMATIC reviews , *PROGNOSIS - Abstract
Summary: This systematic review addresses the prognostic significance of neck node volume in head and neck cancer. Primary tumor volume evolved as an independent significant factor for survival in head and neck cancer patients. Besides primary tumor volume, multiple prognostic features related to the regional lymph nodes were studied in literature. In literature, some authors showed the significance of total tumor volume/nodal volume for survival and loco-regional control. Articles reporting prognosis and survival in nodal tumor volumes were collected by systematically reviewing publications listed in the Pubmed and Embase databases. Publications were included when they at least reported on total tumor volume (TTV) or nodal volume and survival. In this systematic review we studied 21 articles. For measurement of nodal volume different formulas were used. Until now, there’s no clear statistical evidence for the use of either TTV or nodal volume versus primary tumor volume to predict the individual loco-regional control or survival after treatment. There is wide variety of tumor measuring systems in the literature. The cut-off value for local tumor response also shows large variation. Firstly consensus should be accomplished on standardization of volume measurements, preferably automatic, and secondly large study groups are needed with identical treatment modalities to further unravel the role of neck node volume as separate staging tool. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.